— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion.
— For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to be $10.65 to $10.85.
— ALXN stock gained 1.8% during pre-market hours immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key highlights from Adobe (ADBE) Q2 2021 earnings results
Adobe Systems Incorporated (NASDAQ: ADBE) reported second quarter 2021 earnings results today. Total revenue grew 23% year-over-year to $3.84 billion. GAAP net income was $1.11 billion, or $2.32 per share,
Three factors that bode well for Delta Air Lines (DAL) going forward
Shares of Delta Air Lines Inc. (NYSE: DAL) have gained 45% over the past 12 months and 11% since the beginning of this year. After a particularly distressful period, like
KR Earnings: All you need to know about Kroger Q1 2021 earnings results
The Kroger Co. (NYSE: KR) reported first-quarter 2021 earnings results today. Total company sales were $41.3 billion compared to $41.5 billion in the same period last year. Excluding fuel, sales
